Last reviewed · How we verify

Tice Bcg — Competitive Intelligence Brief

Tice Bcg (bcg) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]. Area: Oncology.

marketed Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages. Oncology Live · refreshed every 30 min

Target snapshot

Tice Bcg (bcg) — Pfizer.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tice Bcg TARGET bcg Pfizer marketed Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.
Tice Bcg bacillus-calmette-guerin Pfizer marketed Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] Mycobacterium tuberculosis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] class)

  1. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tice Bcg — Competitive Intelligence Brief. https://druglandscape.com/ci/bcg. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: